ALB and COVID-19: In contrast, the GSEA results also indicated an anti-SARS-CoV-2 effect of PG2 via a reduction in the gene set of the COVID-19 adverse outcome pathway (WikiPathways—WP4891), maturation of the SARS-CoV-2 S protein (Reactome—R-HSA-9694548), translation of SARS-CoV-2 structural proteins (Reactome—R-HSA-9694635), and SARS-CoV-2 infection (Reactome—R-HSA-9694516) (Table 1, Supplementary Figure S1A–D).